Moderna Inc (MRNA)

Moderna Inc Stock (MRNA) dropped by 2.30% from $78.96 to $77.14 in the trading on Tuesday November 21, 2023. The reason why MRNA stock down today is due to Moderna patent invalidated in European Patent Office dispute. Reuters reported that the European Patent Office (EPO) has invalidated one of Moderna's (MRNA) patents related to COVID-19 vaccine technology in a patent dispute with rival BioNTech (BNTX) and its partner Pfizer (PFE). Moderna has disagreed with the EPO's decision and is appealing the ruling. The invalidation of this patent could have a significant impact on Moderna's future earnings, as the company relies heavily on its COVID-19 vaccine for revenue.

Moderna INC Stock (MRNA) dropped by 4.23% from $86.01 to $82.37 in the trading on Thursday October 19, 2023. The reason why MRNA stock down today is due to the outlook for its COVID-19 vaccine sales. Investors' concerns are due to the news that on Oct. 13, Pfizer lowered its full-year 2023 guidance because of weaker sales expectations for COVID products Comirnaty and Paxlovid. With Pfizer now more pessimistic, investors appear to be bracing for Moderna's COVID-19 vaccine sales to be near the low end of its forecast range.

Shares of Moderna (MRNA) dropped by 6.10% from $91.94 to $86.33 in the trading on Tuesday, October 17, 2023. The reason why MRNA stock down is due to investors' growing concerns and negative sentiment. While Moderna maintained its full-year outlook for COVID-19 vaccine sales, investors are apprehensive about the company's prospects in a post-pandemic world. The uncertainty surrounding Moderna's ability to sustain vaccine sales beyond the pandemic has contributed to the downward pressure on its stock.

Shares of Moderna INC (MRNA) dropped by 6.47% from $98.30 to $91.94 in the trading on Monday, October 16, 2023. The reason why MRNA stock down is due to a competitor's announcement. Pfizer Inc. revised its full-year sales outlook, cutting $9 billion from its projections. Pfizer's decision to focus on its Paxlovid COVID treatment and other factors led to this adjustment. Pfizer's stock also experienced a decline of 2.8% before the market opened on Monday, following a significant drop in after-hours trading on Friday. The impact extended to other pharmaceutical companies, including Moderna Inc. shares falling in response to Pfizer's announcement.

Moderna Inc. (MRNA) experienced a significant 9.12% decline (from $114.59 to $104.14), ranking as the poorest performer in both the S&P 500 and Nasdaq 100 today. This drop was in response to a less optimistic vaccination demand forecast than originally anticipated.

https://finance.yahoo.com/m/85bb6f7a-89a7-3b8e-bdf7-fa97419cb800/moderna-pfizer-stocks-fall.html

Moderna's (NASDAQ: MRNA) stock saw a 2.5% increase following the positive results of its experimental mRNA cancer vaccine, which demonstrated a significant reduction in the risk of death or recurrence of the most fatal form of skin cancer.

https://www.cnbc.com/2023/04/17/stocks-moving-big-midday-googl-schw-stt-mrna-enph.html